Jack Meehan
Stock Analyst at Barclays
(3.08)
# 1,300
Out of 4,735 analysts
131
Total ratings
68.29%
Success rate
21.26%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $234 → $249 | $243.99 | +2.05% | 11 | Oct 25, 2024 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $152.57 | -18.07% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $413.81 | -30.40% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $21.77 | +51.58% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $141.31 | +129.99% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $16.96 | +12.03% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $152.65 | -35.15% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $205.07 | -12.23% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $12.57 | -20.45% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $205.69 | -19.30% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $43 | $70.37 | -38.89% | 9 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $169.81 | -9.31% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $348.95 | +23.23% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $353.86 | +21.52% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $43.72 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $60.07 | -20.09% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,324.48 | -48.66% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $105.69 | -71.62% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $573.06 | -47.65% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $1.73 | +2,218.57% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 25, 2024
Maintains: Equal-Weight
Price Target: $234 → $249
Current: $243.99
Upside: +2.05%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $152.57
Upside: -18.07%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $413.81
Upside: -30.40%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $21.77
Upside: +51.58%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $141.31
Upside: +129.99%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $16.96
Upside: +12.03%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $152.65
Upside: -35.15%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $205.07
Upside: -12.23%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $12.57
Upside: -20.45%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $205.69
Upside: -19.30%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $70.37
Upside: -38.89%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $169.81
Upside: -9.31%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $348.95
Upside: +23.23%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $353.86
Upside: +21.52%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $43.72
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $60.07
Upside: -20.09%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,324.48
Upside: -48.66%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $105.69
Upside: -71.62%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $573.06
Upside: -47.65%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $1.73
Upside: +2,218.57%